Fotemustine + bevacizumab as second-line treatment in glioma: a phase II study

Trial Profile

Fotemustine + bevacizumab as second-line treatment in glioma: a phase II study

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Fotemustine (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Aug 2015 New trial record
    • 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top